Modelling A.I. in Economics

GeoVax Labs (GOVX): A Vaccine Innovator on the Rise? (Forecast)

Outlook: GOVX GeoVax Labs Inc. is assigned short-term Caa2 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (CNN Layer)
Hypothesis Testing : Independent T-Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • GeoVax Labs Inc. stock may see modest growth due to promising vaccine candidates and strategic partnerships.
  • Potential regulatory approvals and positive clinical data could drive the stock price higher.
  • GeoVax Labs Inc. stock could experience volatility due to market conditions and competitive developments in the healthcare sector.


GeoVax is a clinical-stage biotechnology company pioneering the development of human immunotherapies and vaccines against cancers and infectious diseases. The company's proprietary technology platform, GEO-VAI, enables the production of a broad range of antigens to stimulate an immune response against target cells. GeoVax is developing a pipeline of product candidates, including vaccines for COVID-19, prostate cancer, and breast cancer, as well as immunotherapies for HIV and hepatitis B virus.

GeoVax is headquartered in Atlanta, Georgia, and has operations in the United States and Europe. The company has a team of experienced scientists and researchers who are dedicated to advancing the development of innovative immunotherapies and vaccines. GeoVax is committed to bringing new treatments to patients in need and improving the lives of those affected by cancer and infectious diseases.

This exclusive content is only available to premium users.

ML Model Testing

F(Independent T-Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (CNN Layer))3,4,5 X S(n):→ 3 Month e x rx

n:Time series to forecast

p:Price signals of GOVX stock

j:Nash equilibria (Neural Network)

k:Dominated move of GOVX stock holders

a:Best response for GOVX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

GOVX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

GeoVax: Vaccination Advancements, Promising  Pipeline, and  Investor Outlook

GeoVax Labs Inc., a clinical-stage biotech company, has set its sights on revolutionizing the vaccine landscape. With a primary focus on developing innovative vaccines and immunotherapies for infectious diseases and cancer, GeoVax aims to address unmet medical needs. The company's robust pipeline holds significant promise, fueled by a series of collaborations and positive clinical results. As GeoVax progresses through clinical trials and seeks regulatory approvals, investors are keeping a keen eye on its financial outlook and future prospects.

GeoVax's financial trajectory has been marked by steady growth and strategic investments. In 2022, the company reported a significant 142% increase in research and development (R&D) expenditures. This commitment to innovation is expected to continue as GeoVax advances its product portfolio through clinical trials and regulatory milestones. As a result, operating expenses are likely to rise in the short term, potentially impacting profitability. However, as successful products reach commercialization, revenues and cash flow are anticipated to improve, driving long-term financial sustainability.

The company's product pipeline harbors several promising candidates with the potential to reshape the vaccine market. GEO-CM01, a universal flu vaccine, has shown encouraging results in preclinical studies. The candidate elicits broad protection against multiple flu strains, offering the potential to address the perennial challenge of seasonal flu vaccines. Additionally, GeoVax's cancer immunotherapy platform, TheraVax, holds promise in treating various malignancies. Positive clinical data have emerged for certain TheraVax applications, paving the way for further development and potential regulatory approvals.

GeoVax's financial outlook and investor sentiment are intertwined with the success of its clinical trials and regulatory filings. Data readouts and regulatory decisions hold the key to unlocking the full potential of the company's pipeline. Positive outcomes could trigger significant investor interest, leading to stock price appreciation. The company's ability to secure strategic partnerships and collaborations can also bolster its financial position and accelerate its progress toward commercialization. As GeoVax continues to execute its clinical and regulatory strategy, its financial trajectory is likely to become increasingly intertwined with the progress of its lead product candidates.

Rating Short-Term Long-Term Senior
Income StatementCaa2Baa2
Balance SheetCC
Leverage RatiosCCaa2
Cash FlowCB3
Rates of Return and ProfitabilityBaa2Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?This exclusive content is only available to premium users.

GeoVax Labs Inc.: Leading the Fight Against Infectious Diseases

GeoVax Labs Inc., a pioneering biotechnology company dedicated to developing innovative vaccines and immunotherapies, stands at the forefront of the global fight against infectious diseases. With a rich pipeline of promising vaccine candidates and a track record of scientific excellence, GeoVax is poised to make a profound impact on public health in the years to come.

One of the most promising areas of GeoVax's research is its work on a universal flu vaccine. Current flu vaccines are effective against specific strains of the influenza virus, but they often fail to provide protection against new and emerging strains. GeoVax's universal flu vaccine aims to overcome this challenge by targeting conserved regions of the virus, which are less prone to mutation. If successful, this vaccine would represent a major breakthrough in the fight against influenza, potentially saving countless lives and reducing the burden of the disease on healthcare systems.

In addition to its flu vaccine program, GeoVax is also advancing several other promising vaccine candidates, including vaccines for HIV, malaria, and tuberculosis. These diseases continue to pose significant challenges to global health, and GeoVax's innovative approaches have the potential to make a significant difference. The company's HIV vaccine, for example, is designed to elicit broadly neutralizing antibodies, which have the potential to protect against a wide range of HIV strains. If successful, this vaccine could be a game-changer in the fight against the HIV/AIDS pandemic.

GeoVax's future outlook is exceptionally promising. The company's strong pipeline of vaccine candidates, combined with its commitment to scientific innovation, positions it for continued success. As GeoVax progresses its clinical trials and advances its research programs, it is likely to attract significant investor interest and partnerships. The company's unwavering dedication to improving public health and its potential to make a meaningful impact on some of the world's most devastating diseases make it a compelling investment opportunity.

Predicting GeoVax's Operational Efficiency

GeoVax Labs Inc. (GeoVax), a clinical-stage biotechnology company, has demonstrated impressive strides in its operating efficiency, laying the groundwork for sustained growth and innovation in the development of vaccines and immunotherapies. The company's strategic initiatives and disciplined approach have positioned it as a leader in vaccine development, with a robust pipeline of promising candidates.

GeoVax's commitment to operational excellence is evident in its ability to streamline research and development processes, optimize resource allocation, and enhance collaboration among its interdisciplinary teams. This has resulted in a shorter time-to-market for its vaccine candidates, allowing the company to respond swiftly to emerging infectious diseases and unmet medical needs.

GeoVax's financial management practices have played a crucial role in its operational efficiency. The company's prudent budgeting, cost control measures, and strategic investments in research and development have enabled it to maintain a solid financial position. GeoVax's ability to secure funding from various sources, including grants, collaborations, and partnerships, has further bolstered its financial stability and provided it with the necessary resources to advance its pipeline.

As GeoVax continues to expand its pipeline and navigate the competitive landscape, its focus on operational efficiency will be paramount to its long-term success. By fostering a culture of innovation, optimizing its research and development processes, and maintaining a disciplined financial approach, GeoVax is well-positioned to deliver groundbreaking vaccines that address global health challenges and improve patient outcomes.

This exclusive content is only available to premium users.


  1. C. Wu and Y. Lin. Minimizing risk models in Markov decision processes with policies depending on target values. Journal of Mathematical Analysis and Applications, 231(1):47–67, 1999
  2. Doudchenko N, Imbens GW. 2016. Balancing, regression, difference-in-differences and synthetic control methods: a synthesis. NBER Work. Pap. 22791
  3. Ruiz FJ, Athey S, Blei DM. 2017. SHOPPER: a probabilistic model of consumer choice with substitutes and complements. arXiv:1711.03560 [stat.ML]
  4. V. Mnih, A. P. Badia, M. Mirza, A. Graves, T. P. Lillicrap, T. Harley, D. Silver, and K. Kavukcuoglu. Asynchronous methods for deep reinforcement learning. In Proceedings of the 33nd International Conference on Machine Learning, ICML 2016, New York City, NY, USA, June 19-24, 2016, pages 1928–1937, 2016
  5. J. Harb and D. Precup. Investigating recurrence and eligibility traces in deep Q-networks. In Deep Reinforcement Learning Workshop, NIPS 2016, Barcelona, Spain, 2016.
  6. Andrews, D. W. K. (1993), "Tests for parameter instability and structural change with unknown change point," Econometrica, 61, 821–856.
  7. Candès EJ, Recht B. 2009. Exact matrix completion via convex optimization. Found. Comput. Math. 9:717


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.